ArticlePsychiatry research2026
Remotely Supervised Home-Based tDCS in Treatment-Resistant Depression: Feasibility, Effectiveness and EEG Biomarkers of Response.
Article in Psychiatry research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
14 authors.
Funding
Abstract
backgroundRemotely supervised home-based transcranial direct current stimulation (HB-tDCS) may expand access to neuromodulation for treatment-resistant depression (TRD), but real-world evidence on candidate biomarkers remains limited.
methodsIn this single-arm pre-post study, 40 adults with major depressive disorder and inadequate response to ≥2 treatments were enrolled. After MRI/clinical screening, 2 were excluded for potential stimulation contraindications and 5 did not start or discontinued within the first sessions for personal reasons unrelated to stimulation. 33 participants completed a 6-week semi-supervised HB-tDCS protocol (42 sessions, 30min, 2mA; anode F3/cathode F4). Baseline and post-treatment assessments included clinician-rated and self-rated depression (MADRS, QIDS-SR16, BDI-II), global cognition (MoCA), quality of life (Q-LES-Q-SF), and neurophysiological markers (resting-state EEG and TMS-EEG). Feasibility, technical incidents, and adverse effects were recorded after each session. Feasibility and safety constituted the primary outcomes; clinical and neurophysiological outcomes were treated as secondary and exploratory endpoints respectively, with biomarker analyses uncorrected for multiple comparisons.
resultsCompleters delivered 1,219/1,386 scheduled sessions (88%). Depressive symptoms decreased from baseline to post-treatment (MADRS -24%, QIDS-SR16 -15%, BDI-II -12%; all p≤.002). Sixteen of 33 (48.5%) achieved ≥25% MADRS reduction (partial response), including 5 (15.2%) with ≥50% reduction. MoCA improved modestly, whereas Q-LES-Q-SF did not change significantly. Adverse effects were mostly mild/moderate (e.g., tingling, headache, scalp dryness), and no stimulation-related serious adverse events occurred. Exploratory analyses suggested higher baseline left-frontal alpha (F3) relative power and candidate TMS-EEG evoked potentials in the left DLPFC (P30, P180) may differentiate responders from non-responders.
conclusionsAn intensive, semi-supervised HB-tDCS program was feasible and well tolerated in TRD and was associated with significant symptom reductions. Candidate EEG/TMS-EEG markers warrant replication in controlled trials.
Indexed as
Identifiers
42580014What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.